FDA Approves CGuard Prime for TCAR, Doubling U.S. Addressable Market
NSPR sits 82% above its 52-week low of $0.425.
Summary
The FDA approved InspireMD's PMA supplement for the CGuard Prime TransCarotid Stent System, clearing the 80 cm delivery system for TCAR procedures when paired with a labeled embolic protection system. This is the approval the company flagged in its September warrant amendments, which tied exercise to the anticipated Q4 2026 FDA decision. The TCAR indication doubles the CGuard Prime platform's U.S. addressable market, adding access to more than 35,000 TCAR procedures a year on top of CAS. Supporting data from the CGUARDIANS II trial showed 100% acute device success with zero death, stroke, MI or stent thrombosis at 30 days. The approval matters most because InspireMD carries a going concern warning and a $75M ATM program; a new revenue indication is the clearest path to funding operations without further dilution. Next up is the CGUARDIANS III trial of SwitchGuard, currently enrolling, which would give InspireMD a fully proprietary stent-plus-neuroprotection TCAR platform if cleared.
At the time of this announcement, NSPR was trading at $0.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36M. The 52-week trading range was $0.43 to $2.22. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.